Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by NKGen Biotech
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
September 12, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
July 30, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference
July 18, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
July 15, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
JNJ
NKGN
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
June 12, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
May 02, 2023
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV
April 14, 2023
From
NKGen Biotech
Via
GlobeNewswire
Tickers
GFOR
NKGen Biotech Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Natural Killer Cell Therapies Targeting Neurodegenerative Diseases
March 08, 2023
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer
January 10, 2023
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech Announces Collaboration with the Parkinson’s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced Parkinson’s Disease
November 04, 2022
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
October 17, 2022
From
NKGen Biotech
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.